AI Frontiers in Cancer Discovery: Unveiling New Horizons in Precision Medicine

Authors

  • Bandoo C Chatale MET Institute of Pharmacy (Degree), Mumbai Author https://orcid.org/0000-0003-2042-5957
  • Yatish Prashant Chauhan MET Institute of Pharmacy (Degree), MET Complex, Bandra Reclamation, Bandra (West), Mumbai 400050, Maharashtra, India Author

Abstract

AI for Cancer Discovery" explores the transformative role of artificial intelligence (AI) in cancer research and treatment. It spotlight the capabilities of CHIEF, an advanced AI model that outperforms traditional diagnostic tools by accurately predicting cancer outcomes across various types. The paper discusses the significance of visual markers in tumor analysis, the impact of computational tools in genetics, and the potential of AI to personalize treatment strategies. By leveraging vast datasets and innovative algorithms, the research aims to enhance understanding, diagnosis, and management of cancer, ultimately improving patient outcomes and revolutionizing global cancer care.

Author Biography

  • Bandoo C Chatale, MET Institute of Pharmacy (Degree), Mumbai

    Dr Bandoo Chatale

    Dr. Bandoo Chatale is an accomplished Pharmaceutical Chemistry professional with an M.S. (Pharm.) in Medicinal Chemistry from NIPER, Mohali, and a Ph.D. (Tech.) in Pharmaceutical Chemistry from ICT, Mumbai. Currently serving as an Assistant Professor at MET Institute of Pharmacy (Degree), Mumbai, he has over five years of academic experience and nearly a year in the pharmaceutical industry at Piramal, Ahmedabad. His expertise spans molecular modeling, co-crystallization, and small molecule synthesis, with six International publications and two books to his credit. Dr. Chatale has guided students in research, served as a consultant to Unilink Pharma, and coordinated multiple academic initiatives, including the Mumbai University Aavishkar Research Convention. Recognized with awards like MET GAURAV and MET PRAGNYAVANT.

    He has mentored five workshop as resource person and delivered invited talks on innovative topics like AI in Pharmaceutical sciences and Understand Taste Perception using Molecular modelling.

    Dr. Chatale's innovative anti-dandruff hair gel project won 2nd runner-up at the 3rd CIIA Innovation Awards in 2024. He holds a granted Design patent and actively participates in faculty development programs and outreach activities.

     

References

1. Jarrahi MH. Artificial intelligence and the future of work: Human-AI symbiosis in organizational decision making. Bus Horiz. 2018;61(4):577–86.

2. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database. 2020;2020:baaa010.

3. Schwalbe N, Wahl B. Artificial intelligence and the future of global health. Lancet. 2020;395(10236):1579–86.

4. Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal SS. Artificial Intelligence–Driven Computational Approaches in the Development of Anticancer Drugs. Cancers (Basel). 2024;16(22):3884.

5. Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Davidson NE, et al. AACR white paper: shaping the future of cancer prevention–a roadmap for advancing science and public health. Cancer Prev Res. 2018;11(12):735–78.

6. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007;7(6):429–40.

7. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537–50.

8. Kannen V, Parry L, Martin FL. Phages enter the fight against colorectal cancer. Trends in cancer. 2019;5(10):577–9.

9. Rižner TL, Thalhammer T, Özvegy-Laczka C. The importance of steroid uptake and intracrine action in endometrial and ovarian cancers. Front Pharmacol. 2017;8:346.

10. Shughart WF. Notorious murders, black lanterns, & moveable goods: the transformation of Edinburgh’s underworld in the early nineteenth century, by Symonds, DA, Series on International Political and Economic History, University of Akron Press: Akron, OH; 2006, xiv+ 180. Manag Decis Econ. 2007;28(2):169–70.

11. Peñaloza OMR, Lewandowska M, Stetefeld J, Ossysek K, Madej M, Bereta J, et al. Apoptins: selective anticancer agents. Trends Mol Med. 2014;20(9):519–28.

12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–7.

13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

14. Clauser SB, Wagner EH, Bowles EJA, Tuzzio L, Greene SM. Improving modern cancer care through information technology. Am J Prev Med. 2011;40(5):S198–207.

15. Sharmila R, Gayathri K. The Transformative Impact of Precision Oncology across Diverse Cancer Types. PEXACY Int J Pharm Sci. 2023;2(12):60–78.

16. LIEVRE A. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2007;66:2643–8.

17. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

18. Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375(12):1109–12.

19. Xu G, Yuan M, Ai C, Liu L, Zhuang E, Karapetyan S, et al. uORF-mediated translation allows engineered plant disease resistance without fitness costs. Nature. 2017;545(7655):491–4.

20. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875–82.

21. Shaw DE, Maragakis P, Lindorff-Larsen K, Piana S, Dror RO, Eastwood MP, et al. Atomic-level characterization of the structural dynamics of proteins. Science (80- ). 2010;330(6002):341–6.

22. Hugen N, Brown G, Glynne-Jones R, de Wilt JHW, Nagtegaal ID. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13(6):361–9.

23. Marquez SB, Thompson K, Lu L, Reisman D. Mechanism of BRG1 silencing in primary cancers. Oncotarget. 2016;7(35):56153.

24. der Auwera V. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinforma. 2013;43:1.

25. Zhao M, Chang J, Liu R, Liu Y, Qi J, Wang Y, et al. miR‐495 and miR‐5688 are down‐regulated in non‐small cell lung cancer under hypoxia to maintain interleukin‐11 expression. Cancer Commun. 2020;40(9):435–52.

26. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–9.

27. Umukoro EE, Apolile FA, Odezuligbo I, Kemefa CO, Umukoro OF. Predicting Cancer Recurrence With Ai-Enhanced Imaging: A Review Of Predictive Models And Their Clinical Implications. (Preprint available at “https://osf.io/preprints/osf/cpheq_v1’ on 01/01/2025)

28. Ho D. Artificial intelligence in cancer therapy. Science (80- ). 2020;367(6481):982–3.

29. Milette S, Quail DF, Spicer JD. Neutrophil DNA webs untangled. Cancer Cell. 2020;38(2):164–6.

30. Chang Y, Park H, Yang HJ, Lee S, Lee KY, Kim TS, et al. Cancer drug response profile scan (CDRscan): a deep learning model that predicts drug effectiveness from cancer genomic signature. Sci Rep. 2018;8(1):8857.

31. Boniolo F, Dorigatti E, Ohnmacht AJ, Saur D, Schubert B, Menden MP. Artificial intelligence in early drug discovery enabling precision medicine. Expert Opin Drug Discov. 2021;16(9):991–1007.

32. Guan J, Gluckman PD. IGF‐1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions. Br J Pharmacol. 2009;157(6):881–91.

33. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (80- ). 2004;304(5676):1497–500.

34. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127–57.

35. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 2021;11(4):900–15.

36. Sharpless NE, Kerlavage AR. The potential of AI in cancer care and research. Biochim Biophys Acta (BBA)-Reviews Cancer. 2021;1876(1):188573.

37. Sharafaddini AM, Esfahani KK, Mansouri N. Deep learning approaches to detect breast cancer: a comprehensive review. Multimed Tools Appl. 2024;1–112.

38. Neha F, Bhati D, Shukla DK, Amiruzzaman M. Chatgpt: Transforming healthcare with ai. AI. 2024;5(4):2618–50.

39. Parums D V. Artificial Intelligence (AI), Digital Image Analysis, and the Future of Cancer Diagnosis and Prognosis. Med Sci Monit Int Med J Exp Clin Res. 2024;30:e947038.

40. Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin cancer Res. 2002;8(5):1085–91.

41. Xie T, Huang A, Yan H, Ju X, Xiang L, Yuan J. Artificial intelligence: illuminating the depths of the tumor microenvironment. J Transl Med. 2024;22(1):799.

42. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. Bmj. 2003;327(7408):195.

43. Hartmaier RJ, Albacker LA, Chmielecki J, Bailey M, He J, Goldberg ME, et al. High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis. Cancer Res. 2017;77(9):2464–75.

44. Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science (80- ). 2022;375(6586):eaay9040.

45. Fan L. Deep Learning for Histopathology Whole Slide Image Analysis. UNSW Sydney; 2024.

46. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9(7):489–99.

47. Landeros C. Machine-Guided Biopsy Analysis in Oncology: Facilitating Diagnostic Access and Biomedical Discovery Through Deep Learning. Massachusetts Institute of Technology; 2024.

48. Shao J, Ma J, Zhang Q, Li W, Wang C. Predicting gene mutation status via artificial intelligence technologies based on multimodal integration (MMI) to advance precision oncology. In: Seminars in cancer biology. Elsevier; 2023. p. 1–15.

49. Akingbola A, Adegbesan A, Ojo O, Otumara JU, Alao UH. Artificial intelligence and cancer care in Africa. J Med Surgery, Public Heal. 2024;3:100132.

50. Singh S, Shukla RM. Artificial Intelligence: The Latest Advances in the Diagnosis of Bladder Cancer. J Urol Oncol. 2024;22(3):268–80.

51. Nguyen PN. Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways. BMC Bioinformatics. 2024;25(1):149.

52. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou M, et al. Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions. Med Res Rev. 2021;41(3):1427–73.

53. Hsu E, Hanson H, Coyle L, Stevens J, Tourassi G, Penberthy L. Machine learning and deep learning tools for the automated capture of cancer surveillance data. JNCI Monogr. 2024;2024(65):145–51.

54. Wang G, Bai Y, Cui J, Zong Z, Gao Y, Zheng Z. Computer-aided drug design boosts RAS inhibitor discovery. Molecules. 2022;27(17):5710.

55. Wang X, Zhao J, Marostica E, Yuan W, Jin J, Zhang J, et al. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature. 2024;634(8035):970–8.

56. Garcia FA de O, Andrade ES de, Palmero EI. Insights on variant analysis in silico tools for pathogenicity prediction. Front Genet. 2022;13:1010327.

57. Iqbal S. The intelligence spectrum: Unraveling the path from ani to asi. J Comput Biomed Informatics. 2024;7(02).

Downloads

Published

2025-03-26

Issue

Vol. 1 (2025): Issue 1, January-March

Section

Articles

How to Cite

AI Frontiers in Cancer Discovery: Unveiling New Horizons in Precision Medicine. (2025). Insights of Pharmatech, 1, 25-36. https://amepurvapub.com/index.php/InsightsPharmatech/article/view/4